Healthcare
Thursday, November 17, 2016
BRIEF-Ra Pharmaceuticals receives orphan drug designation in the European Union for RA101495 for Treatment of Paroxysmal Nocturnal Hemoglobinuria
* Ra Pharmaceuticals receives orphan drug designation in the
European Union for RA101495 for Treatment of Paroxysmal
Nocturnal Hemoglobinuria
Source text for Eikon:
Further company coverage:
Read more
No comments:
Post a Comment
Newer Post
Older Post
Home
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment